Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.
Nature Communications
Berko, Esther R ER; Witek, Gabriela M GM; Matkar, Smita S; Petrova, Zaritza O ZO; Wu, Megan A MA; Smith, Courtney M CM; Daniels, Alex A; Kalna, Joshua J; Kennedy, Annie A; Gostuski, Ivan I; Casey, Colleen C; Krytska, Kateryna K; Gerelus, Mark M; Pavlick, Dean D; Ghazarian, Susan S; Park, Julie R JR; Marachelian, Araz A; Maris, John M JM; Goldsmith, Kelly C KC; Radhakrishnan, Ravi R; Lemmon, Mark A MA; Mossé, Yaël P YP
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.
Nature Communications
Harding, James J JJ; Piha-Paul, Sarina A SA; Shah, Ronak H RH; Murphy, Jessica J JJ; Cleary, James M JM; Shapiro, Geoffrey I GI; Quinn, David I DI; Braña, Irene I; Moreno, Victor V; Borad, Mitesh M; Loi, Sherene S; Spanggaard, Iben I; Park, Haeseong H; Ford, James M JM; Arnedos, Mónica M; Stemmer, Salomon M SM; de la Fouchardiere, Christelle C; Fountzilas, Christos C; Zhang, Jie J; DiPrimeo, Daniel D; Savin, Casey C; Duygu Selcuklu, S S; Berger, Michael F MF; Eli, Lisa D LD; Meric-Bernstam, Funda F; Jhaveri, Komal K; Solit, David B DB; Abou-Alfa, Ghassan K GK
Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection.
Molecular Oncology
Cani, Andi K AK; Dolce, Emily M EM; Darga, Elizabeth P EP; Hu, Kevin K; Liu, Chia-Jen CJ; Pierce, Jackie J; Bradbury, Kieran K; Kilgour, Elaine E; Aung, Kimberly K; Schiavon, Gaia G; Carroll, Danielle D; Carr, T Hedley TH; Klinowska, Teresa T; Lindemann, Justin J; Marshall, Gayle G; Rowlands, Vicky V; Harrington, Elizabeth A EA; Barrett, J Carl JC; Sathiyayogan, Nitharsan N; Morrow, Christopher C; Sero, Valeria V; Armstrong, Anne C AC; Baird, Richard R; Hamilton, Erika E; Im, Seock-Ah SA; Jhaveri, Komal K; Patel, Manish R MR; Dive, Caroline C; Tomlins, Scott A SA; Udager, Aaron M AM; Hayes, Daniel F DF; Paoletti, Costanza C
Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations.
Esmo Open
Riudavets, M M; Sullivan, I I; Abdayem, P P; Planchard, D D
Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations.
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
Cancer Cell
Robichaux, Jacqulyne P JP; Elamin, Yasir Y YY; Vijayan, R S K RSK; Nilsson, Monique B MB; Hu, Lemei L; He, Junqin J; Zhang, Fahao F; Pisegna, Marlese M; Poteete, Alissa A; Sun, Huiying H; Li, Shuai S; Chen, Ting T; Han, Han H; Negrao, Marcelo Vailati MV; Ahnert, Jordi Rodon JR; Diao, Lixia L; Wang, Jing J; Le, Xiuning X; Meric-Bernstam, Funda F; Routbort, Mark M; Roeck, Brent B; Yang, Zane Z; Raymond, Victoria M VM; Lanman, Richard B RB; Frampton, Garrett M GM; Miller, Vincent A VA; Schrock, Alexa B AB; Albacker, Lee A LA; Wong, Kwok-Kin KK; Cross, Jason B JB; Heymach, John V JV
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.
The Lancet. Oncology
Meric-Bernstam, Funda F; Hurwitz, Herbert H; Raghav, Kanwal Pratap Singh KPS; McWilliams, Robert R RR; Fakih, Marwan M; VanderWalde, Ari A; Swanton, Charles C; Kurzrock, Razelle R; Burris, Howard H; Sweeney, Christopher C; Bose, Ron R; Spigel, David R DR; Beattie, Mary S MS; Blotner, Steven S; Stone, Alyssa A; Schulze, Katja K; Cuchelkar, Vaikunth V; Hainsworth, John J
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.
Annals Of Oncology : Official Journal Of The European Society For Medical Oncology
Wang, Y Y; Jiang, T T; Qin, Z Z; Jiang, J J; Wang, Q Q; Yang, S S; Rivard, C C; Gao, G G; Ng, T L TL; Tu, M M MM; Yu, H H; Ji, H H; Zhou, C C; Ren, S S; Zhang, J J; Bunn, P P; Doebele, R C RC; Camidge, D R DR; Hirsch, F R FR
Efficacy of Afatinib in a Previously-Treated Patient with Non-Small Cell Lung Cancer Harboring HER2 Mutation: Case Report.
Journal Of Korean Medical Science
Park, Cheol Kyu CK; Hur, Jae Young JY; Choi, Chang Min CM; Kim, Tae Ok TO; Cho, Hyun Ju HJ; Shin, Hong Joon HJ; Lim, Jung Hwan JH; Choi, Yoo Duk YD; Kim, Young Chul YC; Oh, In Jae IJ
Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.
Genome Research
Brammeld, Jonathan S JS; Petljak, Mia M; Martincorena, Inigo I; Williams, Steven P SP; Alonso, Luz Garcia LG; Dalmases, Alba A; Bellosillo, Beatriz B; Robles-Espinoza, Carla Daniela CD; Price, Stacey S; Barthorpe, Syd S; Tarpey, Patrick P; Alifrangis, Constantine C; Bignell, Graham G; Vidal, Joana J; Young, Jamie J; Stebbings, Lucy L; Beal, Kathryn K; Stratton, Michael R MR; Saez-Rodriguez, Julio J; Garnett, Mathew M; Montagut, Clara C; Iorio, Francesco F; McDermott, Ultan U
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.
Proceedings Of The National Academy Of Sciences Of The United States Of America
Greulich, Heidi H; Kaplan, Bethany B; Mertins, Philipp P; Chen, Tzu-Hsiu TH; Tanaka, Kumiko E KE; Yun, Cai-Hong CH; Zhang, Xiaohong X; Lee, Se-Hoon SH; Cho, Jeonghee J; Ambrogio, Lauren L; Liao, Rachel R; Imielinski, Marcin M; Banerji, Shantanu S; Berger, Alice H AH; Lawrence, Michael S MS; Zhang, Jinghui J; Pho, Nam H NH; Walker, Sarah R SR; Winckler, Wendy W; Getz, Gad G; Frank, David D; Hahn, William C WC; Eck, Michael J MJ; Mani, D R DR; Jaffe, Jacob D JD; Carr, Steven A SA; Wong, Kwok-Kin KK; Meyerson, Matthew M